[go: up one dir, main page]

IS5482A - Composition of active ingredients especially of tetrahydropyridine and acetylcholine esterase inhibitory agent for the treatment of dementia such as Alzheimer's dementia - Google Patents

Composition of active ingredients especially of tetrahydropyridine and acetylcholine esterase inhibitory agent for the treatment of dementia such as Alzheimer's dementia

Info

Publication number
IS5482A
IS5482A IS5482A IS5482A IS5482A IS 5482 A IS5482 A IS 5482A IS 5482 A IS5482 A IS 5482A IS 5482 A IS5482 A IS 5482A IS 5482 A IS5482 A IS 5482A
Authority
IS
Iceland
Prior art keywords
dementia
tetrahydropyridine
alzheimer
treatment
composition
Prior art date
Application number
IS5482A
Other languages
Icelandic (is)
Inventor
Maffrand Jean-Pierre
Soubrie Philippe
Terranova Jean-Paul
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714324A external-priority patent/FR2771006B1/en
Priority claimed from FR9714322A external-priority patent/FR2771007B1/en
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of IS5482A publication Critical patent/IS5482A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS5482A 1997-11-14 2000-05-09 Composition of active ingredients especially of tetrahydropyridine and acetylcholine esterase inhibitory agent for the treatment of dementia such as Alzheimer's dementia IS5482A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9714324A FR2771006B1 (en) 1997-11-14 1997-11-14 COMBINATION OF ACTIVE INGREDIENTS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER TYPE
FR9714322A FR2771007B1 (en) 1997-11-14 1997-11-14 COMBINATION OF ACTIVE INGREDIENTS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER TYPE
PCT/FR1998/002384 WO1999025363A1 (en) 1997-11-14 1998-11-09 Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia

Publications (1)

Publication Number Publication Date
IS5482A true IS5482A (en) 2000-05-09

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5482A IS5482A (en) 1997-11-14 2000-05-09 Composition of active ingredients especially of tetrahydropyridine and acetylcholine esterase inhibitory agent for the treatment of dementia such as Alzheimer's dementia

Country Status (27)

Country Link
EP (1) EP1030671A1 (en)
JP (1) JP2001523642A (en)
KR (1) KR100599350B1 (en)
CN (1) CN1243540C (en)
AU (1) AU743228B2 (en)
BG (1) BG64819B1 (en)
BR (1) BR9814035A (en)
CA (1) CA2309966A1 (en)
CO (1) CO4980891A1 (en)
DZ (1) DZ2649A1 (en)
EA (1) EA003255B1 (en)
EE (1) EE04235B1 (en)
HU (1) HUP0100098A3 (en)
ID (1) ID24933A (en)
IL (2) IL136122A0 (en)
IS (1) IS5482A (en)
MY (1) MY120461A (en)
NO (1) NO20002450L (en)
NZ (1) NZ504420A (en)
OA (1) OA11464A (en)
PL (1) PL194597B1 (en)
SA (1) SA98190747B1 (en)
SK (1) SK286040B6 (en)
TR (1) TR200001262T2 (en)
TW (1) TW585766B (en)
UY (1) UY25247A1 (en)
WO (1) WO1999025363A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4675103B2 (en) * 2002-06-14 2011-04-20 富山化学工業株式会社 Pharmaceutical composition for improving brain function and method for improving brain function
CA2494585A1 (en) * 2002-08-07 2004-02-19 Novartis Ag Methods for the treatment of dementia based on apo e genotype
CN1520818A (en) * 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 Cholinesterase inhibitor pharmaceutical composition for senile dementia
CA2592605C (en) 2004-12-27 2010-12-07 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
CN106163516B (en) 2014-01-31 2019-05-28 考格尼申治疗股份有限公司 Isoindoline compositions and methods of treating neurodegenerative diseases
CN110869011B (en) 2017-05-15 2024-01-05 考格尼申治疗股份有限公司 Compositions for treating neurodegenerative diseases
KR102224918B1 (en) 2018-03-20 2021-03-09 (주)인벤티지랩 Pharmaceutiical composition comprising memantine and donepezil for preventing or treating cognitive impairment-related disease and preparation method thereof
WO2019182319A1 (en) * 2018-03-20 2019-09-26 (주)인벤티지랩 Method for preparing pharmaceutical composition for preventing or treating cognitive disorder-associated diseases, and pharmaceutical composition for preventing or treating cognitive disorder-associated diseases, prepared by preparation method
CN109265391B (en) * 2018-11-13 2021-11-19 枣庄学院 Biphenyl polysubstituted 1,2,5, 6-tetrahydropyridine compound and synthetic method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (en) * 1990-05-22 1994-11-10 Sanofi Sa USE OF 1- [2- (2-NAPHTYL) ETHYL] -4- (3-TRIFLUOROMETHYLPHENYL) -1,2,3,6-TETRAHYDROPYRIDINE FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF BRAIN AND NEURAL DISORDERS.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
JPH11511732A (en) * 1995-03-06 1999-10-12 インターニューロン ファーマシューティカルズ,インコーポレーテッド Reduction of infarct volume using citicoline
FR2736053B1 (en) * 1995-06-28 1997-09-19 Sanofi Sa NEWS 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES

Also Published As

Publication number Publication date
DZ2649A1 (en) 2004-12-28
KR20010032099A (en) 2001-04-16
AU743228B2 (en) 2002-01-24
SA98190747B1 (en) 2006-11-04
CA2309966A1 (en) 1999-05-27
TW585766B (en) 2004-05-01
ID24933A (en) 2000-08-31
BG64819B1 (en) 2006-05-31
IL136122A (en) 2006-07-05
SK286040B6 (en) 2008-01-07
HUP0100098A2 (en) 2001-07-30
EA200000412A1 (en) 2000-12-25
TR200001262T2 (en) 2001-01-22
BG104428A (en) 2001-08-31
SK7112000A3 (en) 2000-10-09
HUP0100098A3 (en) 2001-12-28
EA003255B1 (en) 2003-02-27
KR100599350B1 (en) 2006-07-12
PL340500A1 (en) 2001-02-12
NO20002450L (en) 2000-07-14
AU1160999A (en) 1999-06-07
CN1285742A (en) 2001-02-28
OA11464A (en) 2003-11-18
IL136122A0 (en) 2001-05-20
EP1030671A1 (en) 2000-08-30
NZ504420A (en) 2003-08-29
PL194597B1 (en) 2007-06-29
MY120461A (en) 2005-10-31
NO20002450D0 (en) 2000-05-11
EE04235B1 (en) 2004-02-16
EE200000290A (en) 2001-06-15
WO1999025363A1 (en) 1999-05-27
CO4980891A1 (en) 2000-11-27
JP2001523642A (en) 2001-11-27
CN1243540C (en) 2006-03-01
UY25247A1 (en) 2001-05-31
BR9814035A (en) 2000-09-26

Similar Documents

Publication Publication Date Title
DK1123313T3 (en) Methods and compositions for the prevention and treatment of anemia
DE69612185D1 (en) BLEACHING METHOD AND BLENDER COMPOSITION
DE69739583D1 (en) TOPICAL COMPOSITIONS CONTAIN AS A THERAPEUTICALLY ACTIVE AGENT A MONOGLYCERIDE FOR THE TREATMENT OF SLEW-TONE INFECTIONS
DE69728594D1 (en) Chromium-free composition for the treatment of metal surfaces
DK0622408T3 (en) Composition and process for the preparation of gelatin-free soft capsules
DE69638351D1 (en) AS WELL AS FOR RESISTING THE DISTAL AND FRONT FEMUR
DE69413051D1 (en) DETERGENT COMPOSITIONS CONTAINING AGENTS FOR PREVENTING THE TURNING OF SILVER
DE69718668D1 (en) LIQUID COMPOSITION, INCLUDING HIV PROTEASE INHIBITORS AND C12-C18 FATTY ACID
DK0667330T3 (en) Cyclohexanol derivative, agent and composition containing it for imparting pleasant cooling sensation, process for the preparation of the derivative and intermediate thereof
DE69617088D1 (en) Process for the preparation of crystallized maltitol and crystallines containing it.
DE69812784D1 (en) Composition for the prevention and elimination of plant diseases
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
IS5482A (en) Composition of active ingredients especially of tetrahydropyridine and acetylcholine esterase inhibitory agent for the treatment of dementia such as Alzheimer's dementia
DE69831788D1 (en) Process for the preparation of semi-transparent mixtures of poly-phenyleoxides and styrenic copolymers
DE69420229D1 (en) Pharmaceutical composition for the treatment of AIDS
NO992504D0 (en) Compositions for the treatment of soil, process for its preparation, and use
NO20001758D0 (en) Methods and compositions for the treatment of arthritis
DK0918521T3 (en) Formulation for the treatment and / or prevention of dementia
DE69802498D1 (en) COMBINATION PRODUCT CONTAINING IDEBENON FOR ALZHEIMER TREATMENT
WO2000033788A3 (en) Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
EP0635567A3 (en) Method and composition for facilitating the removal of soil contaminants from solid surfaces.
FI944687A7 (en) Composition for the prevention and treatment of myopia
DE69408394D1 (en) 4-piperidino-piperidine for the treatment of tumors
NO981499L (en) Process for the preparation of titanium dioxide
IT1283124B1 (en) PHARMACEUTICAL FORMS AND COMPOSITIONS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY